Cancer: A limited role for dual EGFR and ErbB2 inhibition in cholangiocarcinoma?

摘要

A preclinical study indicates that combinations of targeted therapies with erbB receptor tyrosine kinase inhibitors might have limited efficacy in patients with advanced cholangiocarcinoma. "Under particular conditions, dual targeting of EGFR and ErbB2 could be a potentially useful strategy for cholangiocarcinoma therapy, but such an approach is likely to be ineffective by itself against advanced cancer," says Alphonse Sirica, the study's corresponding author.